635713-71-2

Basic information

• Product Name: 1-N-BOC-5-FORMYL-INDAZOLE
• Synonyms: 1-N-BOC-5-FORMYL-INDAZOLE;1-(tert-Butoxycarbonyl)-1H-indazole-5-carboxaldehyde, 5-Formyl-1H-indazole, N1-BOC protected;1H-Indazole-5-carboxaldehyde, N1-BOC protected;tert-Butyl 5-formyl-1H-indazole-1-carboxylate;1-Boc-indazole-5-carboxaldehyde;1H-INDAZOLE-1-CARBOXYLIC ACID,5-FORMYL-,1,1-DIMETHYLETHYL ESTER
• CAS NO: 635713-71-2
• Molecular Formula: C₁₃H₁₄N₂O₃
• Molecular Weight: 246.26
• Mol File: 635713-71-2.mol

Chemical Properties

• Boiling Point: 390.3°C at 760 mmHg
• Flash Point: 189.8°C
• Appearance: /
• Density: 1.2g/cm³
• Vapor Pressure: 2.68E-06mmHg at 25°C
• Refractive Index: 1.574
• CAS DataBase Reference: 1-N-BOC-5-FORMYL-INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-N-BOC-5-FORMYL-INDAZOLE(635713-71-2)
• EPA Substance Registry System: 1-N-BOC-5-FORMYL-INDAZOLE(635713-71-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 635713-71-2(Hazardous Substances Data)

Usage

Chemical class

Indazoles, which are heterocyclic aromatic compounds.

Substituents

5-formyl group at the 1-position of the indazole ring.

Protecting group

BOC (tert-butoxycarbonyl) group at the N-1 amino group.

Application

Synthesis of pharmaceutical intermediates, agrochemicals, and other fine chemicals.

Advantages

Versatile reactivity, potential pharmacological properties, and a valuable building block in organic chemistry for creating compounds with diverse applications.

InChI:InChI=1/C13H14N2O3/c1-13(2,3)18-12(17)15-11-5-4-9(8-16)6-10(11)7-14-15/h4-8H,1-3H3

Upstream product

• 253801-04-6 1H-indazole-5-carbaldehyde 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 943145-64-0 tert-butyl (Z)-5-(2-(benzyloxycarbonylamino)-3-methoxy-3-oxoprop-1-enyl)-1H-indazole-1-carboxylate 

Relevant articles and documents

Contra-Thermodynamic Positional Isomerization of Olefins

A light-driven method for the contra-thermodynamic positional isomerization of olefins is described. In this work, stepwise PCET activation of a more substituted and more thermodynamically stable olefin substrate is mediated by an excited-state oxidant an

GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS

The present disclosure provides γ-diketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

Catalytic asymmetric syntheses of tyrosine surrogates

(Chemical Equation Presented) Amino acid esters 5-11 as tyrosine mimics have been synthesized in excellent enantioselectivity (up to 99.6% ee) and in good overall chemical yields. The key step in the sequence was the Burk's [Rh(COD)(2R,5R)-Et-DuPhos]BF4-catalyzed asymmetric hydrogenation of enamides with a variety of reactive functional groups.

HETEROARYLAMINO-PHENYLKETONE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS

The present invention relates to compounds that inhibit VEGF receptor tyrosine kinases, especially KDR, pharmaceutical compositions that contain such compounds, methods of treating VEGF receptor kinase-dependent diseases and conditions in mammals using such compounds and composition and methods for their manufacture.

Novel therapeutic agents for the treatment of migraine

The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their u

Calcitonin gene related peptide receptor antagonists

The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS

The presnt invention relates to compounds of Formula (I), as antagonists of calcitonin gene-related peptide receptors ("CGRP-receptor"), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.